300529.SZ
300529.SZ
CNE100002995
JAFRON
Loading chart...

Company Profile

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.

Related stocks

2675.HK
2675.HK • China
EDGE MEDICAL-B
33 HKD
1.64B USD
688139.SS
688139.SS • China
QINGDAO HAIER BIOMEDICAL CO LTD
35.13 CNY
1.66B USD 1Y +4.9%
0853.HK
0853.HK • China
MICROPORT
6.08 HKD
1.48B USD 1Y -59%
2697.HK
2697.HK • China
TH MEDICAL-B
183 HKD
1.2B USD
301363.SZ
301363.SZ • China
Mehow
15.52 CNY
1.85B USD 1Y -10.3%
688016.SS
688016.SS • China
SHANGHAI MICROPORT ENDOVASCULAR
84.9 CNY
1.57B USD 1Y -24.7%
300143.SZ
300143.SZ • China
INKON LIFE
7.95 CNY
1.16B USD 1Y -9%
688626.SS
688626.SS • China
XIANGYU MEDICAL CO LTD
40.49 CNY
969.39M USD 1Y -22.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.9% p.a.
Max Drawdown (5Y)
-74.3%
Sharpe Ratio (5Y)
-0.69
Beta Factor
0.38
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -85.4% in the extended horizon.
ende